ReviewBone marrow transplantation2011
Antifungal prophylaxis in hematopoietic stem cell transplant recipients: the unfinished tale of imperfect success.
Review in Bone marrow transplantation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 46 citations in OpenAlex.
- Voriconazole as primary antifungal prophylaxis in children undergoing allo-SCT.Bone marrow transplantation · 2012Trial
- Effectiveness of posaconazole as primary prophylaxis in allogeneic hematopoietic stem cell transplantation.International journal of hematology · 2026Article
- A case report of the metagenomics next-generation sequencing for early detection of central nervous system mucormycosis with successful rescue in patient with recurrent chronic lymphocytic leukemia.Annals of translational medicine · 2022Article
- Systemic antifungal strategies in allogeneic hematopoietic stem cell recipients hospitalized in french hematology units: a post-hoc analysis of the cross-sectional observational AFHEM study.BMC infectious diseases · 2022Article
- Immune Cell Degranulation in Fungal Host Defence.Journal of fungi (Basel, Switzerland) · 2021Review
- Effectiveness and Cost-Effectiveness of Prophylactic Voriconazole and Fluconazole Regarding Prevention of Post-hematopoietic Stem Cell Transplantation Invasive Fungal Infection and Its Related Death: A Single Center Experience.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2020Article
- Clinical-scale production of Aspergillus-specific T cells for the treatment of invasive aspergillosis in the immunocompromised host.Bone marrow transplantation · 2019Article
- Article
- Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies.The Journal of antimicrobial chemotherapy · 2018Review
- Fungal Pneumonia in Patients with Hematologic Malignancy and Hematopoietic Stem Cell Transplantation.Clinics in chest medicine · 2017Review
- Methods of Controlling Invasive Fungal Infections Using CD8Frontiers in immunology · 2017Review
- Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011.Antimicrobial agents and chemotherapy · 2014Article
- Predictors of invasive fungal infection in pediatric allogeneic hematopoietic SCT recipients.Bone marrow transplantation · 2014Article
- Secondary Antifungal Prophylaxis in Hematopoietic Stem Cell Transplantation (HSCT)/Acute Leukemia Patients.Current infectious disease reports · 2011Article
- How I treat mucormycosis.Blood · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Antifungal prophylaxis in hematopoietic stem cell transplant recipients is a rapidly evolving field. For this prophylaxis to be beneficial and cost-effective, the risk of a life-threatening invasive fungal infection (IFI) should outweigh the risks of toxic effects and drug interactions introduced by the antifungal agent used. Not all hematopoietic stem cell transplant recipients have the same risk of IFIs. New prophylactic strategies using risk stratification and new broad-spectrum antifungals have the potential for reducing IFI-associated mortality in these patients. Further refinement of risk stratification and risk/benefit analysis (including pharmacoeconomic analysis) is needed. Stratification of IFI risk could be further sharpened based on emerging genetic and metabolic risk factors. However, 10 years after deciphering the human genome, it is unclear whether the genomic revolution would pay off for identifying the SCT recipients at highest risk for IFIs. Empiricism and reliance on institution-specific epidemiologic data are still expected to be a major part of the 'art and science' of risk stratification for fungal infections in SCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.